13 May 2019 - The Biosafety Advisory Council issues a positive advice (with conditions) for this trial
File:
Trial reference:
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Noncentral Nervous System Tumors That are Amenable to Direct Injection